|Mallinckrodt Public Limited Company -- USA Stock|| |
USD 32.82 0.66 2.05%
Sr. VP of Global Operations
Dr. Frank Scholz is Executive Vice President of Global Operations and President Specialty Generics of Mallinckrodt Public Limited Company. His responsibilities include global manufacturing operations, quality and supply chain, as well as the Specialty Generics segment. He joined Mallinckrodt in March 2014 as Senior Vice President of Global Operations and assumed his current position in September 2016. Prior to joining Mallinckrodt, Dr. Scholz was a partner with McKinsey Co, a global management consulting firm first in its Hamburg, Germany office and then in its Chicago, Illinois office
Age: 46 SVP Since 2016 Ph.D
44 4246 263 051 http://www.mallinckrodt.com
Scholz was a leader in McKinsey?s global pharmaceutical and operations practices. He joined McKinsey in 1997. Prior to joining McKinsey, Dr. Scholz was a research assistant at the Institute for Management and Accounting at the University of Hanover, Germany.
The company has Return on Asset of 0.03 %
which means that on every $100 spent on asset it made $0.03 of profit. This is way below average. In the same way, it shows return on shareholders equity (ROE)
of 18.2 %
implying that it generated $18.2 on every 100 dollars invested.
The company has 5.86 B in debt with debt to equity (D/E) ratio of 114.9 . This implies that the company may be unable to create cash to meet all of its financial commitments. Mallinckrodt Public Limited Company has Current Ratio of 1.04 demonstrating that it may not be capable to disburse its financial commitments when the payables are due.
Mallinckrodt public limited company develops, manufactures, markets, and distributes branded and generic specialty pharmaceutical solutions and therapies in the United States, Europe, the Middle East, Africa, and internationally. Mallinckrodt Public Limited Company (MNK) is traded on New York Stock Exchange in USA. It is located in IRELAND and employs 4,500 people. Mallinckrodt Public is listed under Pharmaceutical Products category by Fama And French industry classification.